1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

ABCL - 570

Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

$Preview of Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)$

View Poster Contact Presenter

Poster Presenter

Yash Shah

Authors

Yash Shah

Part of Topic

Aggressive B-Cell Lymphoma (ABCL)

Early experience with glofitamab plus polatuzumab vedotin as bridging therapy prior to CD19-directed CAR t-cell therapy in R/R b-cell lymphoma

Yash Shah, Thomas eipe, Hasmukh Jain